Cover Image

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

To analyze the relevance of dynamic susceptibility-weighted contrast-enhanced MRI (DSC-MRI) derived relative cerebral blood volume (rCBV) analysis for predicting response to bevacizumab (BEV) in patients with recurrent glioblastoma (rGB).

Saved in:
Bibliographic Details
Main Authors: Vollmuth, Philipp (Author) , Wiestler, Benedikt (Author) , Burth, Sina (Author) , Wick, Antje (Author) , Nowosielski, Martha (Author) , Heiland, Sabine (Author) , Schlemmer, Heinz-Peter (Author) , Wick, Wolfgang (Author) , Bendszus, Martin (Author) , Radbruch, Alexander (Author)
Format: Article (Journal)
Language:English
Published: 9 March 2015
In: Neuro-Oncology
Year: 2015, Volume: 17, Issue: 8, Pages: 1139-1147
ISSN:1523-5866
DOI:10.1093/neuonc/nov028
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/nov028
Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/neuro-oncology/article/17/8/1139/2324944
Get full text
Author Notes:Philipp Kickingereder, Benedikt Wiestler, Sina Burth, Antje Wick, Martha Nowosielski, Sabine Heiland, Heinz-Peter Schlemmer, Wolfgang Wick, Martin Bendszus, and Alexander Radbruch
Description
Summary:To analyze the relevance of dynamic susceptibility-weighted contrast-enhanced MRI (DSC-MRI) derived relative cerebral blood volume (rCBV) analysis for predicting response to bevacizumab (BEV) in patients with recurrent glioblastoma (rGB).
Item Description:Gesehen am 29.06.2020
Physical Description:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/nov028

Similar Items